NasdaqGS:EXELBiotechs
Margin Gains From Oncology Portfolio Might Change The Case For Investing In Exelixis (EXEL)
Exelixis, Inc. has reported first-quarter 2026 results, with revenue of US$610.81 million and net income of US$210.47 million, alongside higher basic and diluted earnings per share than a year earlier.
The widening gap between revenue and profit compared with the prior-year quarter points to improving operational efficiency and earnings power from Exelixis’s oncology portfolio.
Next, we’ll explore how this margin improvement and earnings growth intersect with Exelixis’s existing investment...